Cyclotek is the leading supplier of radiopharmaceuticals supporting cancer diagnosis and treatment across Australia and New Zealand. The business operates a unique network of GMP-certified cyclotron facilities, enabling the reliable and scalable production of short half-life radioisotopes used in PET imaging. Cyclotek also provides Contract Development and Manufacturing services to global radiopharmaceutical companies, supporting research and clinical trials in nuclear medicine. With critical infrastructure, strong regulatory credentials and an embedded role in essential diagnostic and therapeutic pathways, Cyclotek is a scaled, mission-critical platform at the centre of nuclear medicine in the region.